Kidney Week

Abstract: PUB550

Global Trends in Endothelin A Receptor Antagonist Research for Kidney Disease Management

Session Information

• Publication Only

Category: CKD (Non-Dialysis)

• 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

• Krisanapan, Pajaree, Thammasat University Hospital, Khlong Nueng, Pathum Thani, Thailand

Pajaree Krisanapan, MD

• Suppadungsuk, Supawadee, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Supawadee Suppadungsuk, MD

• Thongprayoon, Charat, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Charat Thongprayoon, MD, FASN

• Fulop, Tibor, Ralph H Johnson VA Health Care System, Charleston, South Carolina, United States

Tibor Fulop, MD, PhD, FASN

• Soliman, Karim, Medical University of South Carolina, Charleston, South Carolina, United States

Karim Soliman, MBChB, MSc, PhD, FASN

• Miao, Jing, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Jing Miao, MD, PhD, FASN

• Cheungpasitporn, Wisit, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Wisit Cheungpasitporn, MD, FASN

Background

Chronic kidney disease (CKD) is a growing global health concern, with millions of people affected worldwide. Endothelin A (ETA) receptor antagonists have shown promise in slowing CKD progression by reducing proteinuria. This study examines the evolution of ETA receptor antagonist research in CKD over the past 30 years, including collaboration patterns, author contributions, and publication trends.

Methods

We conducted a bibliometric analysis of research papers published from 1992 to 2023, focusing on kidney diseases and ETA receptor antagonists. We used specific keywords to identify relevant articles and assessed author contributions using the Y-index, which combines publication numbers and impact.

Results

The findings show a significant increase in collaborative research efforts for ETA Receptor antagonist research in kidney diseases, as evidenced by a rise in the average number of authors per article. The United States emerged as a leading contributor to this research area, with the University of Groningen standing out as a major hub for collaborative projects. Among researchers, H.J.L. Heerspink was recognized for his extensive contributions. Of note, there has been a steady increase in the annual publication rate, culminating in a significant peak in the most recent period.

Conclusion

ETA receptor antagonist research in CKD is characterized by growing global collaboration and a strong focus on understanding and treating this disease. With leading authors and institutions driving research, the future of ETA receptor antagonist therapy for CKD looks promising. Further studies are needed to fully explore the potential of ETA receptor antagonists in slowing CKD progression and improving patient outcomes.